Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action

mBio

Volumn 2, Issue 6, 2011, Pages

  Fichorova, Raina N ^a   Yamamoto, Hidemi S ^a   Delaney, Mary L ^a   Onderdonk, Andrew B ^a   Doncel, Gustavo F ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULOSE SULFATE; HYDROXYETHYLCELLULOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; RANTES; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; ANTIINFECTIVE AGENT; CELLULOSE; CYTOKINE; DRUG DERIVATIVE;

ACTINOBACTERIA; ANTIBACTERIAL ACTIVITY; ARTICLE; ATOPOBIUM VAGINAE; BACTERIAL COLONIZATION; BACTERIAL SURVIVAL; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CRISPATUS; MICROBIAL COLONIZATION; NONHUMAN; PREVOTELLA BIVIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECIES DIFFERENCE; VAGINA FLORA; VAGINITIS; BACTERIUM; BIOLOGICAL MODEL; CELL LINE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MICROBIOLOGY; VAGINA;

ATOPOBIUM VAGINAE; BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS 1; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CRISPATUS; PREVOTELLA BIVIA;

ANTI-INFECTIVE AGENTS; BACTERIA; CELL LINE; CELLULOSE; CYTOKINES; FEMALE; HUMANS; IMMUNITY, INNATE; MODELS, BIOLOGICAL; VAGINA; VAGINOSIS, BACTERIAL;

EID: 84855221338     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00168-11     Document Type: Article

References (68)

1. Fichorova RN, Anderson DJ. 1999. Differential expression of immuno-biological mediators by immortalized human cervical and vaginal epithelial cells. Biol. Reprod. 60:508-514.
2. Fichorova RN, Cronin AO, Lien E, Anderson DJ, Ingalls RR. 2002. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of Toll-like receptor 4-mediated signaling. J. Immunol. 168:2424-2432.
3. Fichorova RN, Desai PJ, Gibson FC, III, Genco CA. 2001. Distinct proinflammatory host responses to Neisseria gonorrhoeae infection in immortalized human cervical and vaginal epithelial cells. Infect. Immun. 69:5840-5848.
4. Fichorova RN, et al. 2006. Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infect. Immun. 74:5773-5779.
5. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. 2005. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol. Rev. 206:306-335.
6. Wira CR, Grant-Tschudy KS, Crane-Godreau MA. 2005. Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am. J. Reprod. Immunol. 53:65-76.
7. Doncel GF, Chandra N, Fichorova RN. 2004. Preclinical assessment of the proinflammatory potential of microbicide candidates. J. Acquir. Immune Defic. Syndr. 37(Suppl. 3): S174-S180.
8. Doncel GF, Clark MR. 2010. Preclinical evaluation of anti-HIV micro-bicide products: new models and biomarkers. Antivir. Res. 88(Suppl. 1): S10-S18.
9. Fichorova RN. 2004. Guiding the vaginal microbicide trials with bio-markers of inflammation. J. Acquir. Immune Defic. Syndr. 37(Suppl. 3): S184-S193.
10. Lard-Whiteford SL, et al. 2004. Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. J. Acquir. Immune Defic. Syndr. 36:541-552.
11. Anderson RA, et al. 2002. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J. Androl. 23: 426-438.
12. Doh AS, et al. 2007. Safety and acceptability of6%cellulose sulfate vaginal gel applied four times per day for 14 days. Contraception 76:245-249.
13. El-Sadr WM, et al. 2006. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS 20:1109-1116.
14. Mauck C, et al. 2001. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety and colposcopy study. Contraception 64:383-391.
15. Schwartz JL, et al. 2006. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception 74:133-140.
16. Scordi-Bello IA, et al. 2005. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 49: 3607-3615.
17. Van Damme L, et al. 2008. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359: 463-472.
18. Cheshenko N, et al. 2004. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob. Agents Chemother. 48:2025-2036.
19. Hladik F, Doncel GF. 2010. Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res. 88(Suppl. 1):S3-S9.
20. Fichorova RN, Tucker LD, Anderson DJ. 2001. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J. Infect. Dis. 184: 418-428.
21. Hedges SR, Barrientes F, Desmond RA, Schwebke JR. 2006. Local and systemic cytokine levels in relation to changes in vaginal flora. J. Infect. Dis. 193:556-562.
22. Nikolaitchouk N, Andersch B, Falsen E, Strömbeck L, Mattsby-Baltzer I. 2008. The lower genital tract microbiota in relation to cytokine-, SLPI-and endotoxin levels: application of checkerboard DNA-DNA hybridization (CDH). APMIS 116:263-277.
23. Witkin SS, Linhares IM, Giraldo P. 2007. Bacterial flora of the female genital tract: function and immune regulation. Best Pract. Res. Clin. Ob-stet. Gynaecol. 21:347-354.
24. Libby EK, Pascal KE, Mordechai E, Adelson ME, Trama JP. 2008. Atopobium vaginae triggers an innate immune response in an in vitro model of bacterial vaginosis. Microbes Infect. 10:439-446.
25. Fichorova RN, et al. 2011. Maternal microbe-specific modulation of inflammatory response in extremely low-gestational-age newborns. mBio 2(1):e00280-10. doi:10.1128/mBio.00280-10.
26. Novak RM, et al. 2007. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women withahigh risk ofheterosexual acquisitionof HIV infection. Clin. Vaccine Immunol. 14:1102-1107.
27. Farquhar C, et al. 2002. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J. Infect. Dis. 186:1173-1176.
28. McNeely TB, et al. 1995. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Invest. 96:456-464.
29. Moutsopoulos NM, Greenwell-Wild T, Wahl SM. 2006. Differential mucosal susceptibility in HIV-1 transmission and infection. Adv. Dent. Res. 19:52-56.
30. Semba RD, et al. 1999. Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women. J. Hum. Lact. 15: 301-306.
31. Shugars DC, Sauls DL, Weinberg JB. 1997. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. Oral Dis. 3(Suppl. 1):S70-S72.
32. Shugars DC, Wahl SM. 1998. The role of the oral environment in HIV-1 transmission. J. Am. Dent. Assoc. 129:851-858.
33. Skott P, Lucht E, Ehnlund M, Björling E. 2002. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism. Oral Dis. 8:160-167.
34. Wahl SM, et al. 1997. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Dis. 3(Suppl. 1):S64-S69.
35. Wahl SM, et al. 1997. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. Am. J. Pathol. 150:1275-1284.
36. Halpern V, et al. 2008. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 3:e3784.
37. Verstraelen H, et al. 2009. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatuspromotes the stability ofthe normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol. 9:116.
38. Zeichner SL. 2011. HIV human vaginal microbicide effects on the vaginal microbial community. Keystone Symposia:Protection from HIV: Targeted Intervention Strategies," Whistler, BC, Canada.
39. Simoes JA, et al. 2002. Two novel vaginal microbicides (polystyrene sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes commonly associated with bacterial vaginosis. Antimicrob. Agents Chemother. 46:2692-2695.
40. Herold BC, et al. 2000. Poly(sodium 4-styrene sulfonate): an effective candidate topical antimicrobial for the prevention of sexually transmitted diseases. J. Infect. Dis. 181:770-773.
41. Tao W, Richards C, Hamer D. 2008. Enhancement of HIV infection by cellulose sulfate. AIDS Res. Hum. Retroviruses 24:925-929.
42. Van Damme L, Taylor D. 2008. Cellulose sulfate for prevention of HIV infection. N. Engl J. Med. 359:2066-2068.
43. Kaul R, et al. 2008. Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility. AIDS 22: 2049-2051.
44. Capobianchi MR, et al. 1998. Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages. AIDS Res. Hum. Retroviruses 14:233-240.
45. + T cells. Science 270:1811-1815.
46. Coffey MJ, Woffendin C, Phare SM, Strieter RM, Markovitz DM. 1997. RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. Am. J. Physiol. 272:L1025-L1029.
47. Lehner T. 2002. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol. 23: 347-351.
48. Moriuchi H, Moriuchi M, Fauci AS. 1997. Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J. Immunol. 158:3483-3491.
49. Vangelista L, Secchi M, Lusso P. 2008. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine 26:3008-3015.
50. Iqbal SM, et al. 2005. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J. Infect. Dis. 192:728-738.
51. Rebbapragada A, et al. 2008. Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment. J. Ac-quir. Immune Defic. Syndr. 49:520-522.
52. Verhelst R, et al. 2005. Comparison between Gram stain and culture for the characterization of vaginal microflora: definition of a distinct grade that resembles grade I microflora and revised categorization of grade I microflora. BMC Microbiol. 5:61.
53. Levin J, Bang FB. 1968. Clottable protein in Limulus; its localization and kinetics of its coagulation by endotoxin. Thromb. Diath. Haemorrh. 19: 186-197.
54. Fichorova RN, et al. 2004. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol. Reprod. 71: 761-769.
55. Fichorova RN, Rheinwald JG, Anderson DJ. 1997. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol. Reprod. 57:847-855.
56. Fichorova RN, et al. 2005. Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation. Antimicrob. Agents Chemother. 49: 323-335.
57. Canny GO, Trifonova RT, Kindelberger DW, Colgan SP, Fichorova RN. 2006. Expression and function of bactericidal/permeability-increasing protein in human genital tract epithelial cells. J. Infect. Dis. 194:498-502.
58. Trifonova RT, Pasicznyk JM, Fichorova RN. 2006. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Antimicrob. Agents Chemother. 50:4005-4010.
59. Onderdonk AB, et al. 1987. Qualitative assessment of vaginal microflora during use of tampons of various compositions. Appl. Envir Microbiol. 53:2779-2784.
60. Klein G, Pack A, Bonaparte C, Reuter G. 1998. Taxonomy and physiology of probiotic lactic acid bacteria. Int. J. Food Microbiol. 41:103-125.
61. Senok AC, Verstraelen H, Temmerman M, Botta GA. 2009. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst. Rev. CD006289. http://www2.cochrane.org/reviews/en/ab006289.html.
62. Antonio MA, Hawes SE, Hillier SL. 1999. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J. Infect. Dis. 180:1950-1956.
63. Spear GT, et al. 2008. Comparison of the diversity of the vaginal micro-biota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis. J. Infect. Dis. 198:1131-1140.
64. Murray PR (ed). 1995. Manual of clinical microbiology. ASM Press, Washington, DC.
65. Delaney ML, Onderdonk AB. 2001. Nugent score related to vaginal culture in pregnant women. Obstet. Gynecol. 98:79-84.
66. Onderdonk AB, Lee ML, Lieberman E, Delaney ML, Tuomala RE. 2003. Quantitative microbiologic models for preterm delivery. J. Clin. Micro-biol. 41:1073-1079.
67. Fichorova RN, Ross RA. 2002. Vaginal microbiota regulates epithelial proinflammatory pathways. Keystone Symposia. NF-kappaB: Bench to Bedside. Keystone Symposia for Molecular and Cellular Biology, Keystone, Colorado.
68. Li J, Yuan J. 2008. Caspases in apoptosis and beyond. Oncogene 27: 6194-6206.